Evidence map›Paper›PMID 27573114›Full record

ArticleNature microbiology2016

The binary toxin CDT enhances Clostridium difficile virulence by suppressing protective colonic eosinophilia.

Carrie A Cowardin, Erica L Buonomo, Mahmoud M Saleh, Madeline G Wilson, Stacey L Burgess, Sarah A Kuehne, Carsten Schwan, Anna M Eichhoff, Friedrich Koch-Nolte, Dena Lyras and 3 more

Open access · greenAbstract read
In one paragraph

Article in Nature microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 122 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
122citing papers in PubMed, 1 pooled it
14.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

122 citing papers in PubMed, 1 synthesis or guideline pooled it, 185 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Biomarkers for Early Severity Prediction inMedicina (Kaunas, Lithuania) · 2026
    Review
  6. Antibiotics promote susceptibility tobioRxiv : the preprint server for biology · 2026
    Article
  7. Clostridioides difficile pathogenesis and control.Nature reviews. Microbiology · 2026
    Review
  8. Observational
  9. Review
  10. Review
  11. Review
  12. Gut microbes · 2025
    Article
  13. Article
  14. The emerging view on the roles of butyrate inInfection and immunity · 2025
    Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. iMetaOmics · 2025
    Review

62 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 4 countries.

Carrie A CowardinDepartments of Microbiology, Immunology and Cancer Biology, University of Virginia Health System, Charlottesville, Virginia 22908 USA.ORCID 0000-0002-8225-8261
Erica L BuonomoDepartments of Microbiology, Immunology and Cancer Biology, University of Virginia Health System, Charlottesville, Virginia 22908 USA.
Mahmoud M SalehDepartments of Microbiology, Immunology and Cancer Biology, University of Virginia Health System, Charlottesville, Virginia 22908 USA.
Madeline G WilsonDepartments of Microbiology, Immunology and Cancer Biology, University of Virginia Health System, Charlottesville, Virginia 22908 USA.
Stacey L BurgessDepartments of Microbiology, Immunology and Cancer Biology, University of Virginia Health System, Charlottesville, Virginia 22908 USA.
Sarah A KuehneClostridia Research Group, Centre for Biomolecular Sciences, University of Nottingham, Nottingham NG7 2RD, UK.
Carsten SchwanInstitute of Experimental and Clinical Pharmacology and Toxicology, Albert-Ludwigs-University of Freiburg, Freiburg, Germany.
Anna M EichhoffInstitute of Immunology, University Medical Center Hamburg-Eppendorf, D20246 Hamburg, Germany.
Friedrich Koch-NolteInstitute of Immunology, University Medical Center Hamburg-Eppendorf, D20246 Hamburg, Germany.
Dena LyrasDepartment of Microbiology, Infection and Immunity Program, Monash Biomedicine Discovery Institute, and Monash University, Victoria 3800, Australia.
Klaus AktoriesInstitute of Experimental and Clinical Pharmacology and Toxicology, Albert-Ludwigs-University of Freiburg, Freiburg, Germany.
Nigel P MintonClostridia Research Group, Centre for Biomolecular Sciences, University of Nottingham, Nottingham NG7 2RD, UK.
William A PetriDepartments of Microbiology, Immunology and Cancer Biology, University of Virginia Health System, Charlottesville, Virginia 22908 USA.
University of Virginia Health System · USUniversität Hamburg · DEUniversity of Freiburg · DEUniversity of Nottingham · GBDiscovery Institute · US

Funding

INFECTIOUS DISEASES TRAINING PROGRAMT32AI007046 · NIAID · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Alison K Criss, William A Petri · 1985 to 2026
$15.3M
INTERDISCIPLINARY TRAINING PROGRAM IN IMMUNOLOGYT32AI007496 · NIAID · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Michael G. Brown, Coleen A McNamara · 1995 to 2026
$10.2M
BIOTECHNOLOGY TRAINING PROGRAMT32GM008715 · NIGMS · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI LAURIE, GORDON WILLIAM · 2000 to 2019
$6.6M
STRUCTURE/FUNCTION OF E HISTOLYTICA ADHERENCE LECTINR01AI026649 · NIAID · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI PETRI, WILLIAM A · 1989 to 2016
$6.1M
Role of Type 2 Immunity in Innate Protection from C. difficileR01AI124214 · NIAID · UNIVERSITY OF VIRGINIA · PI William A Petri · 2016 to 2026
$5.4M
Role of IL-23 in the Immunopathogenesis of C. difficile colitisR21AI114734 · NIAID · UNIVERSITY OF VIRGINIA · PI PETRI, WILLIAM A · 2015 to 2016
$422k
The Role of IL-23 in the Pathogenesis of Clostridium difficile InfectionF31AI114203 · NIAID · UNIVERSITY OF VIRGINIA · PI BUONOMO, ERICA L · 2014 to 2015
$52k
Medical Research Council G0601176NIAID NIH HHS F31 AI114203NIAID NIH HHS R01 AI026649NIAID NIH HHS R01 AI124214NIAID NIH HHS R21 AI114734NIAID NIH HHS T32 AI007046NIAID NIH HHS T32 AI007496NIGMS NIH HHS T32 GM008715
6 · The paper itself

Abstract

Clostridium difficile is the most common hospital acquired pathogen in the USA, and infection is, in many cases, fatal. Toxins A and B are its major virulence factors, but expression of a third toxin, known as C. difficile transferase (CDT), is increasingly common. An adenosine diphosphate (ADP)-ribosyltransferase that causes actin cytoskeletal disruption, CDT is typically produced by the major, hypervirulent strains and has been associated with more severe disease. Here, we show that CDT enhances the virulence of two PCR-ribotype 027 strains in mice. The toxin induces pathogenic host inflammation via a Toll-like receptor 2 (TLR2)-dependent pathway, resulting in the suppression of a protective host eosinophilic response. Finally, we show that restoration of TLR2-deficient eosinophils is sufficient for protection from a strain producing CDT. These findings offer an explanation for the enhanced virulence of CDT-expressing C. difficile and demonstrate a mechanism by which this binary toxin subverts the host immune response.

Indexed as

ADP Ribose TransferasesAnimalsBacterial ProteinsClostridioides difficileClostridium InfectionsColonDisease Models, AnimalEosinophilsMiceRibotypingVirulence Factorsactin-specific ADP-ribosyltransferase, ClostridiumADP Ribose TransferasesBacterial ProteinsVirulence Factors

Identifiers

PMID27573114
PMCPMC5010011
OpenAlexW2460827612

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.